Monaco Asset Management SAM Buys 39,000 Shares of Inogen, Inc. (NASDAQ:INGN)

Monaco Asset Management SAM increased its holdings in shares of Inogen, Inc. (NASDAQ:INGN) by 104.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 76,500 shares of the medical technology company’s stock after purchasing an additional 39,000 shares during the quarter. Monaco Asset Management SAM owned approximately 0.32% of Inogen worth $702,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Inogen by 312.5% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 174,625 shares of the medical technology company’s stock worth $1,694,000 after purchasing an additional 132,287 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Inogen by 2.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock valued at $8,692,000 after purchasing an additional 23,891 shares during the period. Barclays PLC lifted its stake in Inogen by 72.9% in the 3rd quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock valued at $539,000 after purchasing an additional 23,398 shares during the last quarter. Geode Capital Management LLC grew its holdings in Inogen by 1.1% during the third quarter. Geode Capital Management LLC now owns 554,191 shares of the medical technology company’s stock worth $5,377,000 after purchasing an additional 5,921 shares during the period. Finally, Franklin Resources Inc. bought a new position in Inogen during the third quarter worth about $139,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Needham & Company LLC reiterated a “hold” rating on shares of Inogen in a report on Wednesday, February 26th. StockNews.com cut Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th.

Inogen Stock Performance

Inogen stock opened at $7.45 on Friday. Inogen, Inc. has a 52 week low of $6.14 and a 52 week high of $13.33. The stock has a market capitalization of $197.65 million, a P/E ratio of -3.31 and a beta of 1.15. The stock has a 50-day simple moving average of $10.01 and a 200 day simple moving average of $9.91.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.